ConductScience.org, home

Paper28052849

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.

Alobaid AS and 11 others. Antimicrob Agents Chemother, 2017. Cited by 63 papers, by iCite.

Cite this record

ConductScience Library. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Papers, record 28052849. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28052849

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2017
PubMed
Publication types
Journal Article, Observational Study
PubMed
Citations, by iCite
63
iCite
Relative citation ratio, by iCite
3.55
iCite
Revised in PubMed
2018-12-02
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alobaid ASAbdulaziz S
2Wallis SCSteven C
3Jarrett PPaul
4Starr TTherese
5Stuart JJanine
6Lassig-Smith MMelissa
7Mejia JLJenny Lisette Ordóñez
8Roberts MSMichael S
9Roger CClaire
10Udy AAAndrew A
11Lipman JJeffrey
12Roberts JAJason A

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Bacterial InfectionsMajor topic
Obesity, MorbidMajor topic
Penicillanic AcidMajor topic
PiperacillinMajor topic
Adult
Aged
Biological Availability
Body Mass Index
Creatinine
Critical Illness
Drug Administration Schedule
Drug Dosage Calculations
Female
Humans
Infusions, Intravenous
Linear Models
Male
Microbial Sensitivity Tests
Middle Aged
Monte Carlo Method
Piperacillin, Tazobactam Drug Combination

Source PubMed

Download CSV of topics

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123404393Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.J Pharmacokinet Pharmacodyn2013https://conductscience.org/library/papers/23404393PubMed
216940077
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16940077PubMed
325747553Prevalence of class-I, class-II and class-III obesity in Australian adults between 1995 and 2011-12.Obes Res Clin Pract2015https://conductscience.org/library/papers/25747553PubMed
415335147Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations.Perit Dial Int2004https://conductscience.org/library/papers/15335147PubMed
520018492First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.Int J Antimicrob Agents2010https://conductscience.org/library/papers/20018492PubMed
617785973Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.Chemotherapy2007https://conductscience.org/library/papers/17785973PubMed
723864417Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.Pharmacotherapy2014https://conductscience.org/library/papers/23864417PubMed
812650399Risk factors for surgical site infection in spinal surgery.J Neurosurg2003https://conductscience.org/library/papers/12650399PubMed
925038549The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.Adv Drug Deliv Rev2014https://conductscience.org/library/papers/25038549PubMed
1026988339Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.Int J Antimicrob Agents2016https://conductscience.org/library/papers/26988339PubMed
1115255794What is the best size descriptor to use for pharmacokinetic studies in the obese?Br J Clin Pharmacol2004https://conductscience.org/library/papers/15255794PubMed
1226702922What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?J Antimicrob Chemother2016https://conductscience.org/library/papers/26702922PubMed
1323228881Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.Int J Antimicrob Agents2013https://conductscience.org/library/papers/23228881PubMed
1411481298Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.J Antimicrob Chemother2001https://conductscience.org/library/papers/11481298PubMed
151244564Prediction of creatinine clearance from serum creatinine.Nephron1976https://conductscience.org/library/papers/1244564PubMed
1623188954Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia.Indian J Crit Care Med2012https://conductscience.org/library/papers/23188954PubMed
1717547502Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.Expert Rev Anti Infect Ther2007https://conductscience.org/library/papers/17547502PubMed
1815548157Postoperative infections and antibiotic prophylaxis for hysterectomy in Sweden: a study by the Swedish National Register for Gynecologic Surgery.Acta Obstet Gynecol Scand2004https://conductscience.org/library/papers/15548157PubMed
1920065329Three decades of beta-lactamase inhibitors.Clin Microbiol Rev2010https://conductscience.org/library/papers/20065329PubMed
2021333028Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.BMC Anesthesiol2011https://conductscience.org/library/papers/21333028PubMed

See all 31 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.

PMIDTitleJournalYearIn PapersSource
42802803
Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study.
Drug Des Devel Ther2026https://conductscience.org/library/papers/42802803PubMed
41649772β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses.Clin Pharmacokinet2026https://conductscience.org/library/papers/41649772PubMed
41463740Seventeen Years of an Antibiotic Stewardship Programme: Trends in Antibiotic Prescribing and Gram-Negative Bacilli Susceptibility at a Quaternary Healthcare Institution.Antibiotics (Basel)2025https://conductscience.org/library/papers/41463740PubMed
39912647Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/39912647PubMed
39699210Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/39699210PubMed
39628093Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.J Clin Pharmacol2025https://conductscience.org/library/papers/39628093PubMed
39334976Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review.Antibiotics (Basel)2024https://conductscience.org/library/papers/39334976PubMed
38902929Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing.Clin Infect Dis2024https://conductscience.org/library/papers/38902929PubMed
38560542The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients With Obesity.Hosp Pharm2023https://conductscience.org/library/papers/38560542PubMed
38543252Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin.Pharmaceutics2024https://conductscience.org/library/papers/38543252PubMed
38436564Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.Clin Microbiol Rev2024https://conductscience.org/library/papers/38436564PubMed
38180719Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action.Clin Pharmacokinet2024https://conductscience.org/library/papers/38180719PubMed
36978398Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients.Antibiotics (Basel)2023https://conductscience.org/library/papers/36978398PubMed
36978342Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria.Antibiotics (Basel)2023https://conductscience.org/library/papers/36978342PubMed
36498473
Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.
J Clin Med2022https://conductscience.org/library/papers/36498473PubMed
35946096Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.Curr Med Chem2023https://conductscience.org/library/papers/35946096PubMed
35924928Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35924928PubMed
35724128
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
J Antimicrob Chemother2022https://conductscience.org/library/papers/35724128PubMed
35625262Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn.Antibiotics (Basel)2022https://conductscience.org/library/papers/35625262PubMed
35453185Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.Antibiotics (Basel)2022https://conductscience.org/library/papers/35453185PubMed

See all 38 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28052849

GET https://conductscience.org/api/papers/v1/28052849/references?page=2